{ "@context": "https://schema.org", "@type": "Project", "datePublished": "2020-09-23", "dateModified": "2020-12-11", "name": "Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for
a rapid review", "headline": "Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for
a rapid review", "author": "Folkehelseinstituttet", "image": "", "hideImage":"False", "publisher": { "@type": "Organization", "name": "Folkehelseinstituttet", "logo": { "@type": "ImageObject", "url": "https://www.fhi.no/contentassets/c03aa76fe30941f08474ee823ba2a928/logo-norsk-hel-navnet-uten-luft-rundt.png" } } }

Tests for detection of ROS1 gene alterations in patients with non-small cell lung cancer - Protocol for a rapid review

The NIPH will evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer.

About the project

Project period: 23.09.2020 - 15.02.2021 (Concluded)
Coordinating Institution: Norwegian Institute of Public Health
Project Manager:
- Gerd Monika Flodgren, Norwegian Institute of Public Health
Project Participants:
- Vida Hamidi, Norwegian Institute of Public Health
- Elisabet Vivianne Hafstad, Norwegian Institute of Public Health
Project plan: ROS1 projectplan.pdf
- See more information and results in the Norwegian Research Information Repository (NVA)

Summary

The Institute of Public Health has been commissioned to evaluate genomic tests relevant for the identification of somatic ROS1 gene alterations in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). The Norwegian Medicines Agency (NoMA) will evaluate the treatment effect and safety of the drug Entrectinib (Rozlytrek) in the same population.